June 27, 2025

Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?

The phase III NRG Oncology GOG-0263 trial—results of which were presented during the Plenary Session of the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer—examined whether...

The ASCO Post

June 27, 2025

Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers

“Advanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with PD-1 inhibitors reported in C...

The ASCO Post

June 27, 2025

Relacorilant and Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

In a phase III trial (ROSELLA) reported in The Lancet, Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorila...

The ASCO Post

June 27, 2025

Patient-Reported Outcomes With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer

An analysis of the phase III MIRASOL trial evaluated quality-of-life outcomes in patients receiving mirvetuximab soravtansine vs chemotherapy for FRα-positive, platinum-resistant ovarian cancer.

The ASCO Post

June 27, 2025

Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma

In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine s...

The ASCO Post

March 30, 2023

Time-Related and Financial Burdens May Impact Quality of Life for Patients With Gynecologic Cancer

Time-related and financial burdens may be detrimental to the quality of life of patients with gynecologic cancer as well as cancer survivors, according to the findings from two new studies presented b...

The ASCO Post

May 11, 2023

Institute Research Shines at Society of Gynecologic Oncology Annual Meeting

Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.

Dana-Farber

March 28, 2024

Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

The phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial investigated the efficacy and safety of adding pembrolizumab to chemoradiotherapy in patients with newly diagnosed, high-risk, locally advanced cerv...

The ASCO Post

April 25, 2024

Expert Point of View: Gini F. Fleming, MD

Exciting updates from the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer highlight significant improvements in advanced or recurrent endometrial cancer treatment, particularly for patients with specific genetic profiles. Leading expert Dr. Gini F. Fleming shares insights on new approaches and ongoing trials.

The ASCO Post